Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunogen Inc
(NQ:
IMGN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunogen Inc
< Previous
1
2
3
4
5
Next >
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
February 01, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
January 04, 2023
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Susan Altschuller on FMLA Leave; Interim CFO Appointed
December 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare Conference
December 27, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH
December 10, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia
December 09, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
November 21, 2022
From
ImmunoGen, Inc.
Via
Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
December 01, 2022
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
November 14, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
November 04, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Departure of Chief Commercial Officer
November 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
October 28, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
October 20, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
September 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
September 14, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
September 11, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
August 31, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
July 29, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results
July 14, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates
June 13, 2022
From
ImmunoGen Inc.
Via
Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO
May 26, 2022
From
ImmunoGen, Inc.
Via
Business Wire
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
May 25, 2022
From
ImmunoGen, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.